FDA Accepts Opus Genetics' OPGx-LCA5 into Rare Disease Evidence Principles Program
Event summary
- FDA accepted Opus Genetics' OPGx-LCA5 into the Rare Disease Evidence Principles (RDEP) program on May 4, 2026.
- OPGx-LCA5 is a gene therapy for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease with no approved therapies.
- The RDEP program supports development of therapies for ultra-rare genetic diseases affecting fewer than 1,000 patients in the U.S.
- OPGx-LCA5 has received Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
- Phase 1/2 clinical trial data showed large gains in cone-mediated vision in pediatric participants and durable improvements in adults.
The big picture
Opus Genetics' inclusion in the FDA's RDEP program marks a strategic milestone in the development of therapies for ultra-rare genetic diseases. The program's focus on early collaboration and innovative evidence generation aligns with the challenges of developing treatments for conditions like LCA5, which affect a very small patient population. This move underscores the growing emphasis on regulatory flexibility and efficiency in bringing gene therapies to market for rare diseases.
What we're watching
- Regulatory Alignment
- How the FDA's early collaboration will shape the pivotal Phase 3 program for OPGx-LCA5.
- Clinical Trial Design
- Whether the RDEP program will enable innovative approaches to generating efficacy data in a small patient population.
- Development Pace
- The speed at which Opus Genetics can advance OPGx-LCA5 through the streamlined development pathway.
Related topics